Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk

Sanaei,Sara; Hashemi,Mohammad; Rezaei,Maryam; Hashemi,Seyed  Mehdi; Bahari,Gholamreza; Ghavami,Saeid

doi:10.3892/br.2016.690

Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk

Authors:
- Sara Sanaei
- Mohammad Hashemi
- Maryam Rezaei
- Seyed Mehdi Hashemi
- Gholamreza Bahari
- Saeid Ghavami
View Affiliations

Affiliations: Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan 98167, Iran, Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 98167, Iran, Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan 98167, Iran, Department of Human Anatomy and Cell Science, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
Published online on: May 23, 2016 https://doi.org/10.3892/br.2016.690
Pages: 125-129

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs or miRs) are a family of small non-coding RNAs that function as oncogenes or tumor suppressor genes. Recent evidence suggests that the pri‑miR‑34b/c rs4938723 variant is associated with the development of cancer. At present, there is an inconsistent association between the single‑nucleotide polymorphism in pri-miR-34b/c and cancer in the limited studies. The present study is a case‑control investigation, with 263 breast cancer (BC) patients and 221 control women, which examined the potential association of the pri‑miR‑34b/c rs4938723 polymorphisms with BC susceptibility. The polymorphisms were genotyped by the polymerase chain reaction restriction fragment length polymorphism method. No significant association between the pri‑miR‑34b/c rs4938723 variant and BC was identified [TC vs. TT: Odds ratio (OR), 0.87; 95% confidence interval (CI), 0.60‑1.26; P=0.506; CC vs. TT: OR, 1.22; 95% CI, 0.61‑2.47; P=0.600; TC+CC vs. TT: OR, 0.91; 95% CI, 0.64‑1.31; P=0.648; CC vs. TT+TC: OR, 1.32; 95% CI, 0.67‑2.59; P=0.498; C vs. T: OR, 0.99; 95% CI, 0.75‑1.31; P=0.986]. However, a significant association was observed between the pri‑miR‑34b/c rs4938723 genotypes and clinicopathological characteristics, such a grade, progesterone receptor and human epidermal growth factor receptor 2 status were observed (P<0.05). These findings suggest that the pri‑miR‑34b/c rs4938723 variant may not be a risk factor for the development of BC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, Momtahen AJ, Kashefi A and Ebrahimi M: Twenty years of breast cancer in Iran: Downstaging without a formal screening program. Ann Oncol. 22:93–97. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, Taheri M, Chaabane W, Jain MV and Łos MJ: Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One. 8:e530752013. View Article : Google Scholar : PubMed/NCBI
4	Hashemi M, Eskandari-Nasab E, Fazaeli A, Taheri M, Rezaei H, Mashhadi M, Arbabi F, Kaykhaei MA, Jahantigh M and Bahari G: Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomarkers Med. 6:797–803. 2012. View Article : Google Scholar
5	Hashemi M, Eskandari-Nasab E, Fazaeli A, Rezaei H, Mashhadi MA, Arbabi F and Taheri M: Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 −652 6N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene. 505:176–179. 2012. View Article : Google Scholar : PubMed/NCBI
6	Eskandari-Nasab E, Hashemi M, Rezaei H, Fazaeli A, Mashhadi MA, Moghaddam SS, Arbabi F, Jahantigh M and Taheri M: Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 39:10531–10539. 2012. View Article : Google Scholar : PubMed/NCBI
7	Omrani M, Hashemi M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Arbabi F and Taheri M: hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomarkers Med. 8:259–267. 2014. View Article : Google Scholar
8	Amininia S, Hashemi M, Ebrahimi M, Mashhadi MA, Hashemi SM, Taheri M and Ghavami S: Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of southeast Iranian population. Med Oncol. 31:1892014. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
11	He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al: A microRNA polycistron as a potential human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
12	Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, et al: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 124:1169–1181. 2006. View Article : Google Scholar : PubMed/NCBI
13	Li YQ, Lu JH, Bao XM, Wang XF, Wu JH and Hong WQ: miR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1. J Exp Clin Cancer Res. 34:1302015. View Article : Google Scholar : PubMed/NCBI
14	Ruoming W, Zhen Y, Tengteng Z and Jisheng H: Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2. Cancer Gene Ther. 22:564–572. 2015. View Article : Google Scholar : PubMed/NCBI
15	Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, et al: MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget. 6:36675–36688. 2015.PubMed/NCBI
16	Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
17	Buscaglia LE and Li Y: Apoptosis and the target genes of microRNA-21. Chin J Cancer. 30:371–380. 2011. View Article : Google Scholar : PubMed/NCBI
18	Hashemi M, Sheybani-Nasab M, Naderi M, Roodbari F and Taheri M: Association of functional polymorphism at the miR-502-binding site in the 3′ untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. Tumour Biol. 35:10375–10379. 2014. View Article : Google Scholar : PubMed/NCBI
19	Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, et al: A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 128:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bossard P and Zaret KS: GATA transcription factors as potentiators of gut endoderm differentiation. Development. 125:4909–4917. 1998.PubMed/NCBI
21	Chou J, Provot S and Werb Z: GATA3 in development and cancer differentiation: Cells GATA have it! J Cell Physiol. 222:42–49. 2010. View Article : Google Scholar : PubMed/NCBI
22	He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumour suppressor network. Nature. 447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhu J, Yang L, You W, Cui X, Chen Y, Hu J, Liu W, Li S, Song X, Wei Y, et al: Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China. Int J Clin Exp Pathol. 8:7332–7340. 2015.PubMed/NCBI
24	Zhang J, Huang X, Xiao J, Yang Y, Zhou Y, Wang X, Liu Q, Yang J, Wang M, Qiu L, et al: Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One. 9:e1000552014. View Article : Google Scholar : PubMed/NCBI
25	Ji TX, Zhi C, Guo XG, Zhou Q, Wang GQ, Chen B and Ma FF: miR-34b/c rs4938723 polymorphism significantly decreases the risk of digestive tract cancer: Meta-analysis. Asian Pac J Cancer Prev. 16:6099–6104. 2015. View Article : Google Scholar : PubMed/NCBI
26	Chen P, Sun R, Pu Y, et al: Pri-Mir-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: A case-control study. Medicine (Baltimore). 94:e15362015. View Article : Google Scholar : PubMed/NCBI
27	Pan XM, Sun RF, Li ZH, Guo XM, Qin HJ and Gao LB: Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomarkers. 19:198–202. 2015. View Article : Google Scholar : PubMed/NCBI
28	Lin Z, Chen L, Song M, Shi KQ and Tang KF: Association between a polymorphism in miR-34b/c and susceptibility to cancer - a meta-analysis. Asian Pac J Cancer Prev. 15:7251–7255. 2014. View Article : Google Scholar : PubMed/NCBI
29	Tao T, Chen S, Xu B, Liu C, Wang Y, Huang Y and Chen M: Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: A meta-analysis based on 6,036 cases and 6,204 controls. Chin J Cancer Res. 26:315–322. 2014.PubMed/NCBI
30	Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, Ju X, Meng X, Lu Q, Shao P, et al: A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 29:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
31	Liang TJ, Liu HJ, Zhao XQ, Yu CH and Li CS: Lack of association of miR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: A meta-analysis. PLoS One. 8:e685882013. View Article : Google Scholar : PubMed/NCBI
32	Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR and Millikan RC: Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: The Carolina Breast Cancer Study. Cancer Causes Control. 24:1099–1109. 2013. View Article : Google Scholar : PubMed/NCBI
33	Rezaei M, Hashemi M, Hashemi SM, Mashhadi MA and Taheri M: APOBEC3 deletion is associated with breast cancer risk in a sample of southeast Iranian population. Int J Mol Cell Med. 4:103–108. 2015.PubMed/NCBI
34	Hashemi M, Hanafi Bojd H, Eskandari Nasab E, Bahari A, Hashemzehi NA, Shafieipour S, Narouie B, Taheri M and Ghavami S: Association of adiponectin rs1501299 and rs266729 gene polymorphisms with nonalcoholic fatty liver disease. Hepat Mon. 13:e95272013. View Article : Google Scholar : PubMed/NCBI
35	Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, et al: Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 524:156–160. 2013. View Article : Google Scholar : PubMed/NCBI
36	Liu Q, Yang G, Song XL, Wang Z and Shi G: Association between rs4938723 functional polymorphism in the promoter region of miR-34b/c gene and cancer risk. Clin Res Hepatol Gastroenterol. 39:526–533. 2015. View Article : Google Scholar : PubMed/NCBI
37	Yi DH, Wang BG, Zhong XP, Liu H and Liu YF: Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: Evidence from published data. Tumour Biol. 35:11967–11975. 2014. View Article : Google Scholar : PubMed/NCBI
38	Wang X, Lu X, Fang Y, Chen H, Deng X, Peng C, Li H and Shen B: Association between miR34b/c polymorphism rs4938723 and cancer risk: A meta-analysis of 11 studies including 6169 cases and 6337 controls. Med Sci Monit. 20:1977–1982. 2014. View Article : Google Scholar : PubMed/NCBI
39	Tong N, Chu H, Wang M, Xue Y, Du M, Lu L, Zhang H, Wang F, Fang Y, Li J, et al: Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children. Leuk Lymphoma. 57:1436–1441. 2016. View Article : Google Scholar : PubMed/NCBI